Trial Profile
Comparison of Healing Responses After Treatment of Complex Bifurcation Lesions With a Dedicated Bifurcation Device (Axxess Drug Eluting Coronary Bifurcation Stent System + Biomatrix Drug Eluting Coronary Stent System Stents in the Distal Branches) Versus the Culotte Technique Using Xience Prime Everolimus-eluting Stents : an Optical Coherence Tomography (OCT) Analysis
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 28 Sep 2022
Price :
$35
*
At a glance
- Drugs Umirolimus (Primary) ; Everolimus
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms COBRA
- 20 Jan 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2017 as reported by ClinicalTrials.gov.
- 20 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 05 Dec 2011 Actual initiation date (November 2011) added as reported by ClinicalTrials.gov. (NCT01486095)